Search
Tetrafluoroborate
go.drugbank.com/drugs/DB16340InvestigationalTetrafluoroborate is under investigation in clinical trial NCT02907073 (Positron Emission Tomography (PET) Imaging Studies With NIS Reporter).
Synonyms: Tetrafluoroborate ionCosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell
Synonyms: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-oneEconazole
go.drugbank.com/drugs/DB01127ApprovedIt is used topically in dermatomycoses also orally and parenterally.
Categories: combinations of imidazole derivatives, Metabolic Side Effects of Drugs and SubstancesMebanazine
go.drugbank.com/drugs/DB09248ApprovedWithdrawnIt was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential. … Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B. … [L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770]
Synonyms: SMALL INTERFERING RNA (SIRNA) INHIBITING ANTITHROMBIN LIVER PRODUCTION: DUPLEX OF ((2S,4R)-1-(1-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-16,16-BIS((3-((3-(5-((2-ACETAMIDO-2-DEOXY-.BETA., -D-GALACTOPYRANOSYL)OXY)PENTANAMIDO)PROPYL)AMINO)-3-OXOPRPralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigational[A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … of metastatic RET-fusion positive non-small cell lung cancer.
Probucol
go.drugbank.com/drugs/DB01599ApprovedInvestigationalWithdrawnA drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Categories: Compounds used in a research, industrial, or household settingSynonyms: 4,4'- (Isopropylidenedithio)bis(2,6-di-tert-butylphenol), Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptoleZirconium panitumumab Zr-89
go.drugbank.com/drugs/DB19228InvestigationalZirconium panitumumab Zr-89 is under investigation in clinical trial NCT05423197 (Study Evaluating Zr-panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous
Mercaptopurine
go.drugbank.com/drugs/DB01033ApprovedInvestigationalIt interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. … An antimetabolite antineoplastic agent with immunosuppressant properties.
Categories: combinations of xanthines